Today: 9 June 2026
SSE share price flat at 2,422p as a key trading update looms this week
1 February 2026
1 min read

SSE share price flat at 2,422p as a key trading update looms this week

LONDON, Feb 1, 2026, 09:07 GMT — The market has closed.

SSE (SSE.L) shares closed flat on Friday at 2,422 pence, having hit a 52-week peak of 2,442 pence earlier. Over the past 12 months, the stock has climbed 50.6%. The company also handed out an interim dividend of 21.4 pence per share on Friday.

The utility enters the new week with investors focused on fresh clues about its capital spending — the funds it channels into long-term assets like grids and renewables — and how that’s affecting cash flow. Following a solid rally, any hiccup in execution usually hits the share price quickly.

UK stocks showed some resilience despite a shaky backdrop. The FTSE 100 climbed 0.5% on Friday, marking its seventh consecutive month of gains. At the same time, sterling weakened 0.6% against the dollar, Reuters reported. “The weaker pound is obviously beneficial for the multinationals,” said Fiona Cincotta, senior market analyst at City Index. Reuters

SSE highlighted routine share purchases tied to dividend reinvestment. According to a regulatory notice, several directors and persons discharging managerial responsibilities (PDMRs) used all-employee schemes to reinvest Friday’s dividend, acquiring shares at £24.2328 apiece.

Chief executive Martin Pibworth picked up 19 shares through the share incentive plan and added another 50 via a nominee account, according to the notice. Robert McDonald also bought shares—84 and 35 across the two schemes—while Elizabeth Tanner acquired 65 and 28 respectively.

While these trades are modest, they highlight just how income-focused SSE’s shareholders are, especially when it comes to reinvesting dividends. They also tend to create some volume spikes around payout dates.

What comes next in the company update will carry more weight. Investors want specifics on renewables output, any outages, and how quickly work is progressing in regulated networks. In these areas, the regulator sets allowed returns, but the operator bears the delivery risk.

UK rates add another layer of complexity. The Bank of England will release its February Monetary Policy Report on Feb. 5, a key moment for government bond yields that influence valuations of dividend-rich sectors like utilities.

SSE tends to move alongside other UK utility stocks like National Grid and Centrica, especially when rate shifts dominate over company-specific news during slower periods. Rising yields often make these shares less attractive compared to cash or higher-growth alternatives.

Still, the week’s outcome hinges on fundamentals. Low wind speeds could curb generation, and any indication of rising costs or delays in network expansion might dent confidence—especially with the stock trading close to its peak.

SSE plans to release its third-quarter trading update on Feb. 4, with preliminary results due May 28, according to its financial calendar.

Stock Market Today

  • Soybean Prices Decline Amid Lower Export Shipments and Reduced Speculative Positions
    June 9, 2026, 9:21 AM EDT. Soybean prices fell between 2 and 5 ½ cents on Monday, with the national average cash price dropping to $10.58 3/4 per bushel. Export shipments for the week ending June 4 decreased by 21.2% from the previous week, totaling 398,186 MT, and are down 28.8% year-over-year. Key buyers included Egypt, China, and Mexico. Marketing year exports stand 20.3% lower compared to last year. Meanwhile, speculative traders reduced their net long positions in soybean futures and options by 33,502 contracts, signaling cautious market sentiment. Soymeal and soy oil futures also declined modestly. A private export sale of 264,000 MT was reported for the 2026/27 season, but overall market pressure weighs on prices going into the week.

Latest articles

AT&T Moves Higher Pre-Market on $45 Billion Payout Plan Still in Focus

AT&T Moves Higher Pre-Market on $45 Billion Payout Plan Still in Focus

9 June 2026
AT&T shares edged up to $22.58 pre-market after reaffirming 2026 guidance and a $45B+ shareholder return plan, providing a cash-flow marker as satellite broadband competition looms; the stock remains pressured by SpaceX risks flagged by Oppenheimer, with second-quarter free cash flow seen at $4.0–$4.5B.
GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

9 June 2026
GSK will buy Nuvalent for $10.6 billion in cash, paying a 40% premium, to boost its oncology pipeline ahead of looming HIV drug patent expiries; Nuvalent shares jumped 38.9% premarket while GSK fell 1.4%, with the deal expected to add to GSK sales and profit from 2027 but dilute earnings per share 2026-2028 if it closes in Q3, and final outcome depends on FDA approvals and regulatory clearance.
AmpliTech’s 5G Radio Test Moves AMPG Shares

AmpliTech’s 5G Radio Test Moves AMPG Shares

9 June 2026
AMPG soared 26.7% to $6.57 after AmpliTech revealed its 64T64R Massive MIMO radio was the only one of its kind at O-RAN PlugFest, showing interoperability with major carriers’ equipment, but no new orders were announced, leaving sales conversion as the key investor focus.
Cartesian Growth Ticker Change Draws Trader Attention to Factorial Energy

Cartesian Growth Ticker Change Draws Trader Attention to Factorial Energy

9 June 2026
Factorial Energy surged 16% to $13.80 in its Nasdaq debut as FAC, with premarket trading near $20.70, after replacing CGCT via SPAC merger that raised over $100 million for battery commercialization and implied a $1.3 billion equity value; former CGCT shares now trade as FAC, with founders retaining majority voting power and staged lock-up releases ahead.
Pfizer Falls in Premarket; Fresh FDA Approval Not Lifting the Stock

Pfizer Falls in Premarket; Fresh FDA Approval Not Lifting the Stock

9 June 2026
Pfizer shares fell 1.7% premarket to $25.62 as investors weighed an FDA label expansion for hemophilia drug Hympavzi—now the first subcutaneous non-factor therapy for children 6-11 with hemophilia B—against slower progress in obesity drugs, with mid-stage data for weight-loss shot berobenatide showing a 23.3% vomiting rate and no immediate growth catalyst for the $147 billion company.
Longsys Electronics stock set for Monday test after profit jump forecast and a sharp Friday drop
Previous Story

Longsys Electronics stock set for Monday test after profit jump forecast and a sharp Friday drop

Bitcoin price breaks below $80,000 after silver rout — and Warren Buffett’s Berkshire Hathaway sees American Express nearly catch Apple
Next Story

Bitcoin price breaks below $80,000 after silver rout — and Warren Buffett’s Berkshire Hathaway sees American Express nearly catch Apple

Go toTop